Cargando…
A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study
Purpose: Embolotherapy using microshperes is currently performed with soluble contrast to aid in visualization. However, administered payload visibility dimishes soon after delivery due to soluble contrast washout, leaving the radiolucent bead's location unknown. The objective of our study was...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679352/ https://www.ncbi.nlm.nih.gov/pubmed/26722371 http://dx.doi.org/10.7150/thno.13137 |
_version_ | 1782405566670307328 |
---|---|
author | Duran, Rafael Sharma, Karun Dreher, Matthew R. Ashrafi, Koorosh Mirpour, Sahar Lin, MingDe Schernthaner, Ruediger E. Schlachter, Todd R. Tacher, Vania Lewis, Andrew L. Willis, Sean den Hartog, Mark Radaelli, Alessandro Negussie, Ayele H. Wood, Bradford J. Geschwind, Jean-François H. |
author_facet | Duran, Rafael Sharma, Karun Dreher, Matthew R. Ashrafi, Koorosh Mirpour, Sahar Lin, MingDe Schernthaner, Ruediger E. Schlachter, Todd R. Tacher, Vania Lewis, Andrew L. Willis, Sean den Hartog, Mark Radaelli, Alessandro Negussie, Ayele H. Wood, Bradford J. Geschwind, Jean-François H. |
author_sort | Duran, Rafael |
collection | PubMed |
description | Purpose: Embolotherapy using microshperes is currently performed with soluble contrast to aid in visualization. However, administered payload visibility dimishes soon after delivery due to soluble contrast washout, leaving the radiolucent bead's location unknown. The objective of our study was to characterize inherently radiopaque beads (RO Beads) in terms of physicomechanical properties, deliverability and imaging visibility in a rabbit VX2 liver tumor model. Materials and Methods: RO Beads, which are based on LC Bead® platform, were compared to LC Bead. Bead size (light microscopy), equilibrium water content (EWC), density, X-ray attenuation and iodine distribution (micro-CT), suspension (settling times), deliverability and in vitro penetration were investigated. Fifteen rabbits were embolized with either LC Bead or RO Beads + soluble contrast (iodixanol-320), or RO Beads+dextrose. Appearance was evaluated with fluoroscopy, X-ray single shot, cone-beam CT (CBCT). Results: Both bead types had a similar size distribution. RO Beads had lower EWC (60-72%) and higher density (1.21-1.36 g/cc) with a homogeneous iodine distribution within the bead's interior. RO Beads suspension time was shorter than LC Bead, with durable suspension (>5 min) in 100% iodixanol. RO Beads ≤300 µm were deliverable through a 2.3-Fr microcatheter. Both bead types showed similar penetration. Soluble contrast could identify target and non-target embolization on fluoroscopy during administration. However, the imaging appearance vanished quickly for LC Bead as contrast washed-out. RO Beads+contrast significantly increased visibility on X-ray single shot compared to LC Bead+contrast in target and non-target arteries (P=0.0043). Similarly, RO beads demonstrated better visibility on CBCT in target arteries (P=0.0238) with a trend in non-target arteries (P=0.0519). RO Beads+dextrose were not sufficiently visible to monitor embolization using fluoroscopy. Conclusion: RO Beads provide better conspicuity to determine target and non-target embolization compared to LC Bead which may improve intra-procedural monitoring and post-procedural evaluation of transarterial embolization. |
format | Online Article Text |
id | pubmed-4679352 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-46793522016-01-01 A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study Duran, Rafael Sharma, Karun Dreher, Matthew R. Ashrafi, Koorosh Mirpour, Sahar Lin, MingDe Schernthaner, Ruediger E. Schlachter, Todd R. Tacher, Vania Lewis, Andrew L. Willis, Sean den Hartog, Mark Radaelli, Alessandro Negussie, Ayele H. Wood, Bradford J. Geschwind, Jean-François H. Theranostics Research Paper Purpose: Embolotherapy using microshperes is currently performed with soluble contrast to aid in visualization. However, administered payload visibility dimishes soon after delivery due to soluble contrast washout, leaving the radiolucent bead's location unknown. The objective of our study was to characterize inherently radiopaque beads (RO Beads) in terms of physicomechanical properties, deliverability and imaging visibility in a rabbit VX2 liver tumor model. Materials and Methods: RO Beads, which are based on LC Bead® platform, were compared to LC Bead. Bead size (light microscopy), equilibrium water content (EWC), density, X-ray attenuation and iodine distribution (micro-CT), suspension (settling times), deliverability and in vitro penetration were investigated. Fifteen rabbits were embolized with either LC Bead or RO Beads + soluble contrast (iodixanol-320), or RO Beads+dextrose. Appearance was evaluated with fluoroscopy, X-ray single shot, cone-beam CT (CBCT). Results: Both bead types had a similar size distribution. RO Beads had lower EWC (60-72%) and higher density (1.21-1.36 g/cc) with a homogeneous iodine distribution within the bead's interior. RO Beads suspension time was shorter than LC Bead, with durable suspension (>5 min) in 100% iodixanol. RO Beads ≤300 µm were deliverable through a 2.3-Fr microcatheter. Both bead types showed similar penetration. Soluble contrast could identify target and non-target embolization on fluoroscopy during administration. However, the imaging appearance vanished quickly for LC Bead as contrast washed-out. RO Beads+contrast significantly increased visibility on X-ray single shot compared to LC Bead+contrast in target and non-target arteries (P=0.0043). Similarly, RO beads demonstrated better visibility on CBCT in target arteries (P=0.0238) with a trend in non-target arteries (P=0.0519). RO Beads+dextrose were not sufficiently visible to monitor embolization using fluoroscopy. Conclusion: RO Beads provide better conspicuity to determine target and non-target embolization compared to LC Bead which may improve intra-procedural monitoring and post-procedural evaluation of transarterial embolization. Ivyspring International Publisher 2016-01-01 /pmc/articles/PMC4679352/ /pubmed/26722371 http://dx.doi.org/10.7150/thno.13137 Text en © Ivyspring International Publisher. Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. See http://ivyspring.com/terms for terms and conditions. |
spellingShingle | Research Paper Duran, Rafael Sharma, Karun Dreher, Matthew R. Ashrafi, Koorosh Mirpour, Sahar Lin, MingDe Schernthaner, Ruediger E. Schlachter, Todd R. Tacher, Vania Lewis, Andrew L. Willis, Sean den Hartog, Mark Radaelli, Alessandro Negussie, Ayele H. Wood, Bradford J. Geschwind, Jean-François H. A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
title | A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
title_full | A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
title_fullStr | A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
title_full_unstemmed | A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
title_short | A Novel Inherently Radiopaque Bead for Transarterial Embolization to Treat Liver Cancer - A Pre-clinical Study |
title_sort | novel inherently radiopaque bead for transarterial embolization to treat liver cancer - a pre-clinical study |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4679352/ https://www.ncbi.nlm.nih.gov/pubmed/26722371 http://dx.doi.org/10.7150/thno.13137 |
work_keys_str_mv | AT duranrafael anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT sharmakarun anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT drehermatthewr anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT ashrafikoorosh anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT mirpoursahar anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT linmingde anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT schernthanerruedigere anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT schlachtertoddr anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT tachervania anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT lewisandrewl anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT willissean anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT denhartogmark anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT radaellialessandro anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT negussieayeleh anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT woodbradfordj anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT geschwindjeanfrancoish anovelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT duranrafael novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT sharmakarun novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT drehermatthewr novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT ashrafikoorosh novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT mirpoursahar novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT linmingde novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT schernthanerruedigere novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT schlachtertoddr novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT tachervania novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT lewisandrewl novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT willissean novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT denhartogmark novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT radaellialessandro novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT negussieayeleh novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT woodbradfordj novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy AT geschwindjeanfrancoish novelinherentlyradiopaquebeadfortransarterialembolizationtotreatlivercancerapreclinicalstudy |